Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.51 |
| ▸ | GABRP | O00591 | 4/20 | 0.49 |
| ▸ | GABRD | O14764 | 4/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.49 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.49 |
| ▸ | GABRE | P78334 | 4/20 | 0.49 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.49 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.49 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.49 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.49 |
| ▸ | NAAA | Q02083 | 3/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27435525 | 0.88 | HTR6 (0.52) | HTR6GABRPGABRDGABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL27077852 | 0.87 | HTR6 (0.51) | HTR6GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL31349365 | 0.82 | HTR6 (0.52) | HTR6GPR119 | |
| SCHEMBL3104207 | 0.82 | SOS1 (0.61) | HTR6GPR119SOS1 | |
| SCHEMBL24883385 | 0.80 | HTR6 (0.50) | HTR6GPR119SOS1 | |
| SCHEMBL30169682 | 0.80 | HTR6 (0.50) | HTR6GPR119SOS1 | |
| SCHEMBL195554 | 0.78 | HTR6 (0.53) | HTR6 | |
| SCHEMBL3088134 | 0.78 | SOS1 (0.56) | HTR6GPR119SOS1 | |
| Hydrochloric Acid SCHEMBL4058879 | 0.77 | HTR6 (0.52) | HTR6 | |
| SCHEMBL31349431 | 0.77 | ALDH1A1 (0.58) | HTR6GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156834-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2015-10-13 | — | — | US | disclosed |
| US-9156834-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2015-10-13 | — | — | US | disclosed |
| US-9156834-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2015-10-13 | — | — | US | disclosed |
| US-20140357624-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2014-12-04 | — | — | US | disclosed |
| US-20140357624-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2014-12-04 | — | — | US | disclosed |
| US-20140357624-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2014-12-04 | — | — | US | disclosed |
| US-8846930-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846930-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846930-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2014-09-30 | — | — | US | disclosed |
| EP-2643318-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | Pierre Fabre Médicament (FR) | 2013-10-02 | — | — | EP | disclosed |
| US-20130172326-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| US-20130172326-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| US-20130172326-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| WO-2012069503-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069503-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172326-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | KCNA4, KCNA1, KCNB1 | HTR6 929/4885GPR119 1447/4885GABRP 587/4885 |
| US-20140357624-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | KCNA4, KCNA1, KCNB1 | HTR6 929/4885GPR119 1447/4885GABRP 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.